Evidence map›Paper›PMID 28003746›Full record

ArticleInternational journal of nanomedicine

Evaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma models.

Deborah Michel, Waleed Mohammed-Saeid, Heather Getson, Caitlin Roy, Masoomeh Poorghorban, Jackson M Chitanda, Ronald Verrall, Ildiko Badea

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Deborah MichelDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Waleed Mohammed-SaeidDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Heather GetsonDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Caitlin RoyDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Masoomeh PoorghorbanDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Jackson M ChitandaDepartment of Chemistry, University of Saskatchewan, Saskatoon, SK, Canada.
Ronald VerrallDepartment of Chemistry, University of Saskatchewan, Saskatoon, SK, Canada.
Ildiko BadeaDrug Design and Discovery Research Group, College of Pharmacy and Nutrition.
Drug Discovery Laboratory (Norway) · NOUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel drug delivery systems are developed to improve the biological behavior of poorly soluble drugs and to improve therapeutic outcomes. In melanoma therapy, the goal is efficient drug delivery and mitigation of drug resistance. Melphalan (Mel), a currently used therapeutic agent for melanoma, requires solvent system for solubilization, leading to poor chemical stability. Moreover, drug resistance often renders the drug inefficient in clinical setting. A novel β-cyclodextrin-modified gemini surfactant (CDgemini) delivery system was developed to incorporate Mel in order to improve its physicochemical and biological behavior. Melphalan nanoparticles (Mel-NP) showed optimal particle size in the 200-250 nm range for endocytosis and induced significantly higher cell death compared with Mel (50% of inhibitory concentration [IC

Indexed as

Antineoplastic Agents, Alkylatingbeta-CyclodextrinsCell DeathCell Line, TumorDrug Delivery SystemsDrug Resistance, NeoplasmHumansInhibitory Concentration 50MelanomaMelphalanNanoparticlesParticle SizeQuaternary Ammonium CompoundsSolubilitySurface-Active AgentsAntineoplastic Agents, Alkylatingbeta-CyclodextrinsMelphalanmono-6-O-(3-(bis(3-(N-dodecyl-N,N-dimethylamino)propyl)carbamoyl)propanoyl)-beta-cyclodextrinQuaternary Ammonium CompoundsSurface-Active Agentsanticancer agentapoptosisdrug resistanceflow cytometrylipid nanoparticlesspheroidzeta potential

Identifiers

PMID28003746
PMCPMC5161338
OpenAlexW2565213069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.